Inovio Pharmaceuticals Company Profile (NASDAQ:INO)

Inovio Pharmaceuticals trades on the NASDAQ under the ticker symbol "INO."

Inovio Pharmaceuticals's stock reverse split on the morning of Friday, June 6th 2014. The 1-4 reverse split was announced on Friday, May 23rd 2014. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 5th 2014. An investor that had 100 shares of Inovio Pharmaceuticals stock prior to the reverse split would have 25 shares after the split.

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced its quarterly earnings data on Tuesday, August, 8th. The company reported ($0.13) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.21) by $0.08. The company had revenue of $20.41 million for the quarter, compared to the consensus estimate of $16.29 million. Inovio Pharmaceuticals had a negative net margin of 153.46% and a negative return on equity of 63.67%. The firm's revenue for the quarter was up 229.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.26) earnings per share. View Inovio Pharmaceuticals' Earnings History.

9 equities research analysts have issued 12-month price targets for Inovio Pharmaceuticals' stock. Their predictions range from $11.00 to $40.00. On average, they expect Inovio Pharmaceuticals' share price to reach $22.11 in the next twelve months. View Analyst Ratings for Inovio Pharmaceuticals.

Here are some recent quotes from research analysts about Inovio Pharmaceuticals stock:

• 1. According to Zacks Investment Research, "Inovio is a development-stage biopharmaceutical company is focused on the development of treatments targeting various forms of cancer and infectious diseases. We are pleased with the company’s collaborations with other firms for pipeline development. Shares of Inovio have outperformed the Medical-Biomedical/Genetics industry so far this year. However, Inovio suffered a setback with the FDA placing clinical hold on the proposed phase III program on its lead pipeline candidate, VGX-3100 in Oct 2016. Though in Apr 2017, Inovio submitted a complete response to the FDA for the initiation of the study, FDA decision is still pending. Estimates have been going up lately ahead of the company’s Q2 earnings release. The company has negative record of earnings surprises in recent quarters." (7/11/2017)
• 2. Maxim Group analysts commented, "Inovio announced a collaboration with Roche (RHHBY – $34.10 – NR) to evaluate their DNA-based immunotherapies INO-5401 (multiple cancer antigens) and INO-9012 (IL-12 immune stimulator) with Tecentriq (PD-L1 checkpoint) in advanced bladder cancer." (6/1/2017)

Inovio Pharmaceuticals saw a drop in short interest during the month of July. As of July 31st, there was short interest totalling 8,603,835 shares, a drop of 20.5% from the July 14th total of 10,821,529 shares. Based on an average trading volume of 3,606,177 shares, the short-interest ratio is presently 2.4 days. Approximately 10.2% of the company's shares are short sold.

Some companies that are related to Inovio Pharmaceuticals include Albany Molecular Research (AMRI), Biohaven Pharmaceutical Holding Co Ltd (BHVN), BeyondSpring (BYSI), Immunomedics (IMMU), Editas Medicine (EDIT), Heron Therapeutics (HRTX), Arena Pharmaceuticals (ARNA), Spectrum Pharmaceuticals (SPPI), Cellectis S.A. (CLLS), TG Therapeutics (TGTX), CRISPR THERAPTC (CRSP), Enanta Pharmaceuticals (ENTA), Mesoblast Limited (MESO), Intellia Therapeutics (NTLA), ImmunoGen (IMGN), Kala Pharmctls (KALA), ANI Pharmaceuticals (ANIP) and WAVE Life Sciences (WVE).

Inovio Pharmaceuticals' management team includes the folowing people:

• Jong Joseph Kim Ph.D., President, Chief Executive Officer, Director
• Peter D. Kies, Chief Financial Officer
• Niranjan Y. Sardesai Ph.D., Chief Operating Officer
• Mark L. Bagarazzi M.D., Chief Medical Officer
• Avtar S. Dhillon M.D., Non-Executive Chairman of the Board
• George W. Bickerstaff III, Director
• David B. Weiner, Director
• Simon X. Benito, Independent Director
• Angel Cabrera Ph.D., Independent Director

Inovio Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (4.32%), Wasatch Advisors Inc. (2.89%), State Street Corp (2.40%), Northern Trust Corp (1.20%), Schwab Charles Investment Management Inc. (0.45%) and Bank of New York Mellon Corp (0.44%). Company insiders that own Inovio Pharmaceuticals stock include David B Weiner, Jong Joseph Kim, Morton Collins, Niranjan Sardesai and Simon X Benito. View Institutional Ownership Trends for Inovio Pharmaceuticals.

Inovio Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Stoneridge Investment Partners LLC, New York State Common Retirement Fund, ING Groep NV, TIAA CREF Investment Management LLC, Wells Fargo & Company MN, Russell Investments Group Ltd. and Teachers Advisors LLC. Company insiders that have sold Inovio Pharmaceuticals stock in the last year include David B Weiner, Jong Joseph Kim and Niranjan Sardesai. View Insider Buying and Selling for Inovio Pharmaceuticals.

Inovio Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., Candriam Luxembourg S.C.A., GSA Capital Partners LLP, Vanguard Group Inc., Virtu KCG Holdings LLC, State of Wisconsin Investment Board, Public Employees Retirement System of Ohio and Private Capital Advisors Inc.. Company insiders that have bought Inovio Pharmaceuticals stock in the last two years include Morton Collins and Niranjan Sardesai. View Insider Buying and Selling for Inovio Pharmaceuticals.

Shares of Inovio Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Inovio Pharmaceuticals stock can currently be purchased for approximately $5.36.